{"id":42889,"date":"2026-03-18T16:34:17","date_gmt":"2026-03-18T16:34:17","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/42889\/"},"modified":"2026-03-18T16:34:17","modified_gmt":"2026-03-18T16:34:17","slug":"hims-hers-opens-up-pre-launch-waitlist-for-ozempic-and-wegovy-following-partnership-with-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/42889\/","title":{"rendered":"Hims &#038; Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk"},"content":{"rendered":"<p>The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company\u2019s platform.<\/p>\n<p>Hims &amp; Hers stated earlier this month that the Ozempic and Wegovy offerings will be made available on its platform later in March.The company said that all the available doses of Ozempic injections, and Wegovy pills as well as injections, will be available on the company\u2019s platform at cash pay prices.It said that the prices for these drugs will start at $149 a month.<\/p>\n<p>Hims &amp; Hers Health Inc. (HIMS) on Wednesday announced a pre-launch waitlist for Ozempic and Wegovy following a partnership with Novo Nordisk AS (NVO).<\/p>\n<p>Hims &amp; Hers stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company\u2019s platform.<\/p>\n<p>Interested users can join the waitlist\u00a0<a class=\"st-link-external\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"http:\/\/hims.com\/weight-loss\/waitlist\">here<\/a> or\u00a0<a class=\"st-link-external\" target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/www.forhers.com\/weight-loss\/waitlist\">here<\/a>.<\/p>\n<p>When Will Ozempic And Wegovy Be Available On Hims &amp; Hers?<\/p>\n<p>Hims &amp; Hers stated\u00a0<a href=\"https:\/\/stocktwits.com\/news-articles\/markets\/equity\/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic\/cZdVZe7RIIk\" rel=\"nofollow noopener\" target=\"_blank\">earlier this month<\/a> that the Ozempic and Wegovy offerings will be made available on its platform later in March.<\/p>\n<p>This includes Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg and will also include Wegovy injections in doses of 1.7 mg and 2.4 mg. The Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.<\/p>\n<p>The company stated that it will educate U.S. weight loss customers about their options across a wider range of FDA-approved treatments. When providers determine it is clinically appropriate, Hims &amp; Hers will help support a smooth transition to these medications, it said.<\/p>\n<p>How Much Will Ozempic And Wegovy Cost On Hims &amp; Hers?<\/p>\n<p>Hims &amp; Hers stated that all the available doses of Ozempic injections, and Wegovy pills as well as injections, will be available on the company\u2019s platform at cash pay prices. The telehealth platform added that prices for these drugs will start at $149 a month.<\/p>\n<p>According to Novo Nordisk, Ozempic injections in doses of 0.25 mg and 0.5 mg are available at $199 per month for the first two months for new patients.<\/p>\n<p>Similarly, the Wegovy pill costs $149 per month for the 1.5 mg dose, while the injection costs $199 a month for the first two months for the 0.25 mg and 0.5 mg doses.<\/p>\n<p><a href=\"https:\/\/stocktwits.com\/symbol\/HIMS\" rel=\"nofollow noopener\" target=\"_blank\">HIMS stock<\/a> is down 26% year-to-date, while\u00a0<a href=\"https:\/\/stocktwits.com\/symbol\/HIMS\" rel=\"nofollow noopener\" target=\"_blank\">NOVO stock<\/a> is down 27%. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 19% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF Shares (VB) is up 18%.<\/p>\n<p>Also See:\u00a0<a href=\"https:\/\/stocktwits.com\/news-articles\/markets\/equity\/us-trade-deficit-china-down-30-past-year-jamieson-greer\/cZ37Q0wRIgZ\" rel=\"nofollow noopener\" target=\"_blank\">US Trade Deficit With China Down 30% Over Past Year, Jamieson Greer Reportedly Says: \u2018It Would Be Very Helpful If\u2026\u2019<\/a><\/p>\n<p>For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n<p>Share\u00b7<a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.google.com\/preferences\/source?q=stocktwits.com\" class=\"ShareNewsArticle_hoverState__kkTbC hover|text-blue-ada\">Add us on<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/02\/1771061752_645_icon-google.2109d02c.png\" alt=\"Add us on Google\"\/><\/a><\/p>\n<p>Subscribe to Chart Art<\/p>\n<p>Get the daily email that keeps you tuned in and makes markets fun again.<\/p>\n<p><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.stocktwits.com\/about-newsroom\/\" class=\"NewsArticle_editorialLink__1BMFs hover|text-blue-ada underline w-full text-base\">Read about our editorial guidelines and ethics policy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"The company stated that people who sign up for the waitlist will gain priority access to the official&hellip;\n","protected":false},"author":2,"featured_media":35758,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1440,24309,24307,24308,24310,20757,272,5487,7977,3582,3102,15784,1910,15785],"class_list":{"0":"post-42889","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-hims-hers","9":"tag-hims-hers-novo-nordisk","10":"tag-hims-hers-ozempic","11":"tag-hims-hers-wegovy","12":"tag-hims-shares","13":"tag-hims-stock","14":"tag-novo-nordisk","15":"tag-novo-nordisk-stock","16":"tag-nvo-shares","17":"tag-nvo-stock","18":"tag-ozempic","19":"tag-ozempic-price","20":"tag-wegovy","21":"tag-wegovy-price"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116251149338409983","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/42889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=42889"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/42889\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/35758"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=42889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=42889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=42889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}